High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: A prospective cohort study

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 7, 2016, Pages 577-587

  Langsted, Anne ^a,b   Kamstrup, Pia R ^a,b   Benn, Marianne ^a,b   Tybjærg Hansen, Anne ^a,b,c   Nordestgaard, Børge G ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERINE PROTEINASE; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CRITERION VARIABLE; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FUNDING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; BLOOD; GENETICS; MIDDLE AGED; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84966701498     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30042-0     Document Type: Article

References (30)

1. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331-2339.
2. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
3. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518-2528.
4. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
5. Kronenberg F, Utermann G Lipoprotein(a): resurrected by genetics. J Intern Med 2013, 273:6-30.
6. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478. 390a.
7. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014, 35:2146-2157.
8. Wiklund O, Angelin B, Olofsson SO, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990, 335:1360-1363.
9. Guo HC, Chapman MJ, Bruckert E, Farriaux JP, De Gennes JL Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype. Atherosclerosis 1991, 86:69-83.
10. Lingenhel A, Kraft HG, Kotze M, et al. Concentrations of the atherogenic Lp(a) are elevated in FH. Eur J Hum Genet 1998, 6:50-60.
11. Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014, 35:2249-2259.
12. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015, 372:1489-1499.
13. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014, 63:470-477.
14. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003, 92:152-160. for the STELLAR Study Group.
15. Kinpara K, Okada H, Yoneyama A, Okubo M, Murase T Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. Clin Chim Acta 2011, 412:1783-1787.
16. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012, 97:3956-3964.
17. Watts GF, Sullivan DR, Poplawski N, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl 2011, 12:221-263.
18. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991, 303:893-896. Scientific Steering Committee on behalf of the Simon Broome Register Group.
19. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993, 72:171-176.
20. Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 2016, 37:1384-1394.
21. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013, 381:1293-1301.
22. Kolski B, Tsimikas S Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol 2012, 23:560-568.
23. Rader DJ, Mann WA, Cain W, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995, 95:1403-1408.
24. Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014, 63:1982-1989.
25. Tybjaerg-Hansen A, Jensen HK, Benn M, Steffensen R, Jensen G, Nordestgaard BG Phenotype of heterozygotes for low-density lipoprotein receptor mutations identified in different background populations. Arterioscler Thromb Vasc Biol 2005, 25:211-215.
26. Romagnuolo R, Scipione C, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 2015, 290:1649-1662.
27. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990, 322:1494-1499.
28. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004, 256:482-490.
29. Holmes DT, Schick BA, Humphries KH, Frohlich J Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005, 51:2067-2073.
30. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015, 386:1472-1483.